News

Press Releases

 
Press Releases
  Date Title and Summary View
Oct 6, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will present clinical data from its CRLX101 and CRLX301 programs at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting being ...
Aug 18, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that it is reducing its workforce by approximately 48%, to a total of 23 full-time equivalent employees, under a plan expected to be substantially...
Aug 17, 2016
CRLX101 plus Avastin Does Not Show Improvement Compared to Standard of Care in this Setting Company to Host Conference Call Today at 4:30 pm EDT WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing ...
Aug 4, 2016
Conference Call Today at 4:30 p.m. ET WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities for the quarter ended June 30, 2016. ...
Jul 28, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities for the second quarter 2016 on August 4. Management will conduct a conference ca...
Jul 19, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Cerulean's lead nanoparticle-drug conjugate, CRLX101, in combi...
Jun 23, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has been dosed in the Phase 2a stage of an ongoing Phase 1/2a clinical trial of CRLX301 in patients with advanced solid tum...
Jun 22, 2016
Paper Highlights Preclinical Proof of Concept of CRLX101 in Combination with Avastin® (bevacizumab) in Models of Metastatic Triple-Negative Breast Cancer WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparti...
Jun 14, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Christopher D. T. Guiffre, President & Chief Executive Officer, will present at the JMP Securities Life Sciences Conference in New York City...
Jun 9, 2016
Data from 22 Evaluable Metastatic Renal Cell Carcinoma Patients Treated with CRLX101 in Combination with Avastin® in Phase 1b/2 Investigator-Sponsored Trial Led by University of Pennsylvania WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage ...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
Shareholder Tools